Answers are grounded in this paper and cite their sources.
Background To synthesise, at the level of systematic reviews (SRs) and meta-analyses (MAs), the efficacy of photobiomodulation (PBM)/low-level laser therapy (LLLT) for temporomandibular disorders (TMD), and to appraise the corpus’s methodological quality (AMSTAR-2), primary-study overlap, and dosimetry reporting. Methods Umbrella review of SRs/MAs of PBM/LLLT for TMD (PROSPERO: CRD420261458816). Five databases (Epistemonikos, PubMed/MEDLINE, Lens.org, LILACS, SciELO) were searched from inception to 25 July 2026 without language restriction. Quality was appraised with AMSTAR-2, overlap via corrected covered area (CCA), and dosimetry against a checklist; synthesis was narrative, and certainty was rated with GRADE using the estimates reported by the source meta-analyses. Results Of 231 records, 136 were unique and 32 SRs/MAs met inclusion. Most pooled estimates favoured PBM for short-term pain and maximum mouth opening (MMO; e.g., pain SMD − 0.55, 95% CI − 0.82 to − 0.27, Hanna 2021; MMO MD + 2.78 mm, 1.12 to 4.44, Máximo 2022), but magnitude was highly heterogeneous (I² up to 99%) and metrics non-comparable. Of 30 appraisable, 21 were AMSTAR-2 “Critically Low”, 1 “High”; just 11/32 reported a registered protocol. Across 30 reviews with retrievable study lists, 180 primary trials underpinned the corpus (45% included in ≥ 2 reviews); overall overlap was slight (CCA 5.48%). Wavelength and schedule were reported by 94%, but power density/irradiance (41%) and energy/dose (44%) in fewer than half. Conclusions PBM/LLLT may reduce temporomandibular pain (low certainty, GRADE), but the evidence is very uncertain about the effect on short-term mouth opening (very low certainty), and harms were not assessed. The review-level evidence is numerous but shows only slight primary-study overlap, is mostly of critically low methodological quality, and is inconsistent in reporting delivered-dose parameters. Pre-registered trials that report complete dosimetry would allow future syntheses to estimate the effect and its dose dependence more reliably. Registration PROSPERO CRD420261458816.
No takes yet. Share an insight, caveat, or question.
Bharali et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: